T1	Participants 28 81	prevention of thromboembolism in atrial fibrillation:
T2	Participants 317 366	Stroke Prevention in Atrial Fibrillation (SPAF-I)
T3	Participants 565 593	treatments according to age.
T4	Participants 832 898	715 patients aged 75 years or less and 385 patients older than 75;
T5	Participants 1284 1335	rate of primary events in low-risk younger patients
T6	Participants 1611 1651	3.6% with warfarin and 4.8% with aspirin
T7	Participants 1888 2019	prevention of ischaemic stroke in patients with atrial fibrillation, but the absolute reduction in stroke rate by warfarin is small
T8	Participants 2253 2388	inherent risk of thromboembolism should be considered in the choice of antithrombotic prophylaxis for patients with atrial fibrillation
